ESMO Breast 2021 | 25-year benefit from tamoxifen by clinically used breast cancer markers

Huma Dar and Linda Lindström, MSc, PhD of the Karolinska Institute, Stockholm, Sweden, discuss the findings of a secondary analysis of the STO-3 trial, which aimed to determine the value of clinically used biomarkers in the prediction of long-term survival outcomes in patients with breast cancer. In the STO-3 trial patients with lymph node-negative and ER+/HER2- breast cancer received tamoxifen therapy. The study reported that tumor size and grade are significant predictive factors for 25-year distant recurrence-free interval (DRFI) outcome. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.